Detection of EBV DNA in Non-Hodgkin Lymphoma Patients in Bulgaria
- 6 Downloads
Epstein–Barr virus is the first human oncogenic virus associated with a broad range of different malignant diseases but its role in non-Hodgkin lymphomas (NHL) development still needs to be fully understood. High expression levels of EBV major genes are found in NHL tumor cells and free viral DNA circulates in the plasma of such individuals. In the current study we detected EBV DNA levels in plasma samples from NHL patients in order to validate its significance as a laboratory marker for disease monitoring. We investigated a cohort of 52 patients diagnosed with NHL in The University Hospital “St. Marina” Varna, Bulgaria. Viral DNA was extracted from single plasma samples using Kit Ribo Virus (Sacace Biotechnologies S.r.l., Como, Italy) and amplified with EBV Real-TM Quant (Sacace Biotechnologies S.r.l., Como, Italy). Plasma samples of the same patients were tested for presence of EBV VCA IgM/IgG antibodies with indirect ELISA tests (Euroimmun, Luebeck, Germany). We found 15.4% (95% CI 6.9–28.1%, n = 8) of the samples from NHL patients to be positive in quantitative PCR (range 674–221,333 copies/ml). The diffuse large B cell lymphomas and peripheral T cell lymphomas were most often associated (although not statistically significant, p = 0.167) with detectable plasma EBV DNA levels. To our knowledge, this is the first study about the role of EBV in NHL development in Bulgaria. The results we have obtained should stimulate new, larger investigations to apply the quantitative PCR technique in the routine laboratory EBV diagnosis.
KeywordsEpstein–Barr virus Non-Hodgkin lymphoma EBV DNA
Compliance with Ethical Standards
Conflict of interest
Authors declare absence of any conflict of interest related to this manuscript.
This project received a Grant No 16003/2016 from the Medical University Varna.
The study was approved by the Ethics Committee of the Medical University Varna.
- 2.National Statistical Institute (2018) National center of public health and analyses. Zdraveopazvane, SofiaGoogle Scholar
- 7.Ambinder RF, Mann RB (1994) Detection and characterization of Epstein–Barr virus in clinical specimens. Am J Pathol 145(2):239–252Google Scholar
- 10.An N, Xie Y, Shi P, Xu Y, Qian S (2017) Prognostic significance of circulating plasma Epstein–Barr virus DNA in monitoring aggressive non-Hodgkin’s lymphoma. Int J Clin Exp Med 10(4):6837–6844Google Scholar
- 11.Kim SJ, Choi JY, Hyun SH, Ki C-S, Oh D, Ahn YC et al (2015) Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein–Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. Lancet Haematol 2(2):e66–e74CrossRefGoogle Scholar
- 12.Kim YR, Kim S-J, Cheong J-W, Chung H, Jang JE, Kim Y et al (2017) Pretreatment Epstein–Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. Oncotarget 8(54):92312–92323Google Scholar
- 17.Kostadinova T, Ivanova L, Raykov T, Stojkova Z, Tsankova G (2016) Seroprevalence of Epstein–Barr virus in North-Eastern Bulgaria. Acta Microbiol Bulg 32(3):33–38Google Scholar